<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03464942</url>
  </required_header>
  <id_info>
    <org_study_id>17/013</org_study_id>
    <nct_id>NCT03464942</nct_id>
  </id_info>
  <brief_title>Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer</brief_title>
  <acronym>AZTEC</acronym>
  <official_title>A Randomised Phase II Trial Comparing the Efficacy of Single-fraction or Multi-fraction SABR (Stereotactic Ablative Body Radiotherapy) With AteZolizumab in Patients With Advanced Triple nEgative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter MacCallum Cancer Centre, Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Trans Tasman Radiation Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peter MacCallum Cancer Centre, Australia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre, open label, phase 2, randomised controlled trial of patients with&#xD;
      advanced triple negative breast cancer (TNBC) who have received no more than one line of&#xD;
      chemotherapy (not including neoadjuvant or adjuvant therapy) who will be randomised to be&#xD;
      treated with SABR 20Gy in 1# followed by atezolizumab or SABR 24Gy in 3# followed by&#xD;
      atezolizumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants with triple negative breast cancer will be randomised to receive either SABR 20Gy in one fraction or 24 Gy in 3 fractions , they will then go onto receive atezolizumab for up to 24 months</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>24 months</time_frame>
    <description>To assess the progression free survival of SABR at a dose of 24Gy in 3# followed by atezolizumab and SABR at a dose of 20Gy in 1# followed by atezolizumab in patients with advanced triple negative breast cancer (TNBC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Objective Response (BOR) between different SABR regimens + atezolizumab</measure>
    <time_frame>24 months</time_frame>
    <description>Best objective response (BOR) rate: confirmed complete response (CR) or partial response (PR) as per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events (safety and tolerability)</measure>
    <time_frame>24 months</time_frame>
    <description>Toxicities will be assessed using NCI-CTCAE version 4.03. Tolerability is defined as the time until ceasing treatment due to toxicity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival Comparison between different SABR regimens + atezolizumab</measure>
    <time_frame>24 Months</time_frame>
    <description>To compare the progression free survival between arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) between different SABR regimens + atezolizumab</measure>
    <time_frame>24 months</time_frame>
    <description>Duration of response (DoR), defined as time from first occurrence of documented response to disease progression or death in participants who achieve a PR or better as per RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) between different SABR regimens + atezolizumab</measure>
    <time_frame>24 months</time_frame>
    <description>Disease control (DC), defined as achieving a CR, PR or have had stable disease (SD) for at least 21 weeks prior to any evidence of disease progression, based on RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure between different SABR regimens + atezolizumab</measure>
    <time_frame>24 months</time_frame>
    <description>Time to treatment failure (TTF) defined as the time from randomization until cessation of atezolizumab for any reason including disease progression, treatment toxicity, participant preference or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival between different SABR regimens + atezolizumab</measure>
    <time_frame>24 months</time_frame>
    <description>Overall survival, defined as the time from randomization to the date of death from any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Single Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SABR 20Gy given as a single dose (to 1 -4 metastases with at least 1 untreated metastasis) followed by atezolizumab (1200 mg) every 3 weeks for 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fractionated Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SABR 24Gy given as 3 fractions (to 1 -4 metastases with at least 1 untreated metastasis) followed by atezolizumab (1200 mg) every 3 weeks for 24 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SABR</intervention_name>
    <description>Single Dose Group: this group will receive 20 Gy of radiation in a single dose within 10 days of randomisation Fractionated Dose: Participants in this dose will receive a total of 24Gy of radiation given as 3 separate fractions of 8 Gy each.</description>
    <arm_group_label>Fractionated Dose</arm_group_label>
    <arm_group_label>Single Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>All participants will commence atezolizumab (within 5 days of last SABR dose) 1200 mg every 3 weeks for 24 months</description>
    <arm_group_label>Fractionated Dose</arm_group_label>
    <arm_group_label>Single Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants with a histological or cytological diagnosis of Stage IV TNBC breast&#xD;
             cancer (see Appendix 7), defined by ER &lt;1%, PR &lt;1% and HER2 negative on IHC and/or&#xD;
             non-amplified by ISH by local lab testing.&#xD;
&#xD;
          2. Written informed consent.&#xD;
&#xD;
          3. Male or female participants aged ≥ 18 years and &lt; 70 years.&#xD;
&#xD;
          4. No more than one prior chemotherapy line in the incurable disease setting. For the&#xD;
             purposes of this trial, adjuvant or neoadjuvant chemotherapy does not count as a prior&#xD;
             line of therapy but chemotherapy given for residual disease post neoadjuvant&#xD;
             chemotherapy is considered as one line.&#xD;
&#xD;
          5. Must be 6 or more months from prior adjuvant, neoadjuvant or post neoadjuvant&#xD;
             chemotherapy last dose.&#xD;
&#xD;
          6. At least one measurable lesion as per RECIST 1.1 (see Appendix 1) that is not planned&#xD;
             to receive SABR.&#xD;
&#xD;
          7. CT scan (CAP), while body bone scan, and FDG-PET scan evidence of ≥ 2 metastases (with&#xD;
             ≥ 1 amenable to SABR).&#xD;
&#xD;
          8. Be willing to provide tissue from a newly obtained core biopsy of a metastatic tumour&#xD;
             lesion. Newly-obtained is defined as a specimen obtained up to 60 days prior to&#xD;
             randomisation. Patients for whom newly-obtained samples cannot be provided (e.g.&#xD;
             inaccessible or patient safety concern) may submit an archived specimen only upon&#xD;
             agreement from the CPI).&#xD;
&#xD;
          9. ECOG performance status 0 - 1 (see Appendix 6).&#xD;
&#xD;
         10. Expected life expectancy &gt; 6 months.&#xD;
&#xD;
         11. Female participants of childbearing potential must have a negative urine or serum&#xD;
             pregnancy within 7 days of trial randomisation.&#xD;
&#xD;
         12. Female participants of childbearing potential must be willing to use 2 methods of&#xD;
             birth control or be surgically sterile, or abstain from heterosexual activity for the&#xD;
             course of the trial through to 5 months after the last dose of atezolizumab.&#xD;
&#xD;
         13. Male participants must agree to use an adequate method of contraception starting with&#xD;
             the first SABR treatment, through to 120 days after the last dose of atezolizumab.&#xD;
&#xD;
         14. Adequate Organ Function as defined in the table below:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L,&#xD;
&#xD;
               -  Platelets ≥ 100 x 109/L,&#xD;
&#xD;
               -  Hemoglobin* ≥ 90 g/L OR ≥ 9 g/dL (Without transfusion or EPO dependency (within 7&#xD;
                  days of assessment),&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 X ULN OR Measured or calculated Creatinine Clearance** ≥&#xD;
                  60 mL/min if Serum Creatinine &gt;1.5&#xD;
&#xD;
               -  X ULN (Creatinine clearance should be calculated per institutional standard. GFR&#xD;
                  can also be used in place of creatinine or creatinine clearance - see Attachment&#xD;
                  5 - Cockcroft-Gault Formula),&#xD;
&#xD;
               -  Serum Total Bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN if Serum Total&#xD;
                  Bilirubin &gt; 1.5 ULN&#xD;
&#xD;
        In participants with known Gilbert's syndrome:&#xD;
&#xD;
          -  Serum Total Bilirubin ≤ 3.0 X ULN AND Direct Bilirubin ≤ 1.5 X ULN,&#xD;
&#xD;
          -  Aspartate Aminotransferase (AST/SGOT) and Alanine Aminotransferase (ALT/SGPT) ≤ 2.5 X&#xD;
             ULN OR ≤ 4.0 X ULN if liver metastases are present,&#xD;
&#xD;
          -  Albumin &gt; 221 μmol/L OR &gt; 2.5 mg/dL,&#xD;
&#xD;
          -  International Normalised Ratio (INR) OR Prothrombin Time (PT) OR Activated Partial&#xD;
             Thromboplastin Time (PTT) ≤ 1.5 X&#xD;
&#xD;
          -  ULN unless participant is receiving anticoagulant therapy as long as PT or PTT is&#xD;
             within therapeutic range of intended use of anticoagulants,&#xD;
&#xD;
          -  Lactate dehydrogenase (LDH) ≤2.5 x ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous radiotherapy (BED &gt; 30Gy) to an area to be treated.&#xD;
&#xD;
          2. Evidence of active brain metastases. Participants with previously treated brain&#xD;
             metastases (with surgical resection, stereotactic radiosurgery or palliative whole&#xD;
             brain radiotherapy) may participate, provided they have stable brain metastases&#xD;
             defined as 2 imaging studies documenting stability of brain metastasis(es) over &gt; 4&#xD;
             weeks.&#xD;
&#xD;
          3. Intention to treat or requirement for treatment with any chemotherapy agent within ± 3&#xD;
             weeks of trial treatment.&#xD;
&#xD;
             Note: bisphosphonates or RANKL inhibitors are allowed.&#xD;
&#xD;
          4. Evidence of Spinal Cord Compression.&#xD;
&#xD;
          5. Spinal Instability Neoplastic Score ≥ 7 (see Appendix 4), in a lesion scheduled for&#xD;
             SABR treatment unless lesion reviewed by a neurosurgical service and considered&#xD;
             stable.&#xD;
&#xD;
          6. Untreated lytic metastases in the neck of the femur that erodes the cortex that is&#xD;
             scheduled for SABR treatment.&#xD;
&#xD;
          7. Is currently participating and receiving trial therapy or has participated in a trial&#xD;
             of an investigational agent and is planned to receive trial therapy or used an&#xD;
             investigational device within 4 weeks of trial treatment&#xD;
&#xD;
          8. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             (&gt; or equal to 10mg prednisolone daily) or any other form of immunosuppressive therapy&#xD;
             at time of trial treatment. Note: There must be no intention to commence systemic&#xD;
             long-term steroid therapy or any form of immunosuppressive therapy within 7 days prior&#xD;
             to the planned first dose of atezolizumab treatment. Note: Single (once off) doses of&#xD;
             prophylactic steroid therapy are acceptable.&#xD;
&#xD;
          9. Is planned to receive chemotherapy, targeted small molecule therapy, or radiation&#xD;
             therapy within 3 weeks prior to trial treatment or who has not recovered from adverse&#xD;
             events (i.e. AEs not at ≤ Grade 1 or at baseline values) due to a previously&#xD;
             administered agent.&#xD;
&#xD;
         10. Has a known additional malignancy that is progressing or requires active treatment.&#xD;
&#xD;
         11. Has uncontrolled pleural effusion, pericardial effusion, or ascites requiring&#xD;
             recurrent drainage procedures (once monthly or more frequently).&#xD;
&#xD;
             Note: Participants with indwelling catheters (e.g., PleurX) are allowed.&#xD;
&#xD;
         12. Has uncontrolled hypercalcemia (&gt; 1.5mmol/L ionized calcium or serum calcium&#xD;
             &gt;2.99mmol/L or corrected serum calcium &gt;ULN) or symptomatic hypercalcemia requiring&#xD;
             continued use of bisphosphonate therapy or denosumab. Note: Participants who are&#xD;
             receiving bisphosphonate therapy or denosumab specifically to prevent skeletal events&#xD;
             and who do not have a history of clinically significant hypercalcemia are eligible.&#xD;
&#xD;
         13. Has a significant cardiovascular disease, such as New York Heart Association cardiac&#xD;
             disease (Class II or greater), myocardial infarction within 3 months prior to Cycle 1,&#xD;
             Day 1, unstable arrhythmias or unstable angina. Note: Participants with a known left&#xD;
             ventricular ejection fraction (LVEF) &lt; 40% will be excluded.&#xD;
&#xD;
             Note: Participants with known coronary artery disease, congestive heart failure not&#xD;
             meeting the above criteria, or LVEF &lt; 50% must be on a stable medical regimen that is&#xD;
             optimized in the opinion of the treating physician, in consultation with a&#xD;
             cardiologist if appropriate.&#xD;
&#xD;
         14. Has a history of autoimmune disease, including but not limited to myasthenia gravis,&#xD;
             myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis,&#xD;
             inflammatory bowel disease, vascular thrombosis associated with anti-phospholipid&#xD;
             syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome,&#xD;
             multiple sclerosis, vasculitis, or glomerulonephritis.&#xD;
&#xD;
             Note: Participants with a history of autoimmune hypothyroidism on a stable dose of&#xD;
             thyroid replacement hormone are eligible Note: Participants with controlled Type 1&#xD;
             diabetes mellitus on a stable insulin regimen are eligible Note: Participants with&#xD;
             eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic&#xD;
             manifestations only (e.g., participants with psoriatic arthritis would be excluded)&#xD;
             are permitted provided that they meet the following conditions:&#xD;
&#xD;
               -  Rash must cover less than 10% of body surface area (BSA).&#xD;
&#xD;
               -  Disease is well controlled at baseline and only requiring low potency topical&#xD;
                  steroids.&#xD;
&#xD;
               -  No acute exacerbations of underlying condition within the previous 12 months (not&#xD;
                  requiring PUVA [psoralen plus ultraviolet A radiation], methotrexate, retinoids,&#xD;
                  biologic agents, oral calcineurin inhibitors, high-potency or oral steroids).&#xD;
&#xD;
         15. Has a history of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced&#xD;
             pneumonitis, organising pneumonia (i.e., bronchiolitis obliterans, cryptogenic&#xD;
             organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan.&#xD;
&#xD;
             Note: History of radiation pneumonitis in the radiation field (fibrosis) is permitted.&#xD;
&#xD;
         16. Has an active infection requiring systemic therapy.&#xD;
&#xD;
         17. Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the participant's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the participant to participate, in the opinion of the treating investigator.&#xD;
&#xD;
         18. Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
         19. Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial, starting with the pre-screening or screening visit&#xD;
             through to 5 months after or 120 days after the last dose of trial treatment, for&#xD;
             women and men respectively.&#xD;
&#xD;
         20. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.&#xD;
&#xD;
         21. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).&#xD;
&#xD;
         22. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA&#xD;
             [qualitative] is detected).&#xD;
&#xD;
         23. Administration of a live, attenuated vaccine within 4 weeks prior to Cycle 1, Day 1 or&#xD;
             anticipation that such a live attenuated vaccine will be required during the study -&#xD;
             Influenza vaccination should be given during influenza season only (example:&#xD;
             approximately March to October in the Southern Hemisphere). Participants must not&#xD;
             receive live, attenuated influenza vaccine (e.g., FluMist®) within 4 weeks prior to&#xD;
             Cycle 1, Day 1 or at any time during the study treatment or within 5 months after the&#xD;
             last dose of atezolizumab.&#xD;
&#xD;
         24. Has a known history of active TB (Bacillus Tuberculosis).&#xD;
&#xD;
         25. Known hypersensitivity to atezolizumab or its excipients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherene Loi, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peter MacCallum Cancer Centre, Australia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherene Loi, Prof</last_name>
    <phone>+61 3 8559 5935</phone>
    <email>sherene.loi@petermac.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steven David, Dr</last_name>
    <phone>+61 3 9928 8924</phone>
    <email>steven.david@petermac.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven David, Dr</last_name>
      <phone>+61 3 9928 8924</phone>
      <email>steven.david@petermac.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 21, 2018</study_first_submitted>
  <study_first_submitted_qc>March 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2018</study_first_posted>
  <last_update_submitted>January 31, 2021</last_update_submitted>
  <last_update_submitted_qc>January 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

